Opinion

Video

Unmet Needs and Treatment Gaps in Prostate Cancer

Author(s):

Benjamin H. Lowentritt, MD, FACS,Brian Richardson, MD

The panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods.

Current Time 0:00
Duration 5:16
Loaded: 3.11%
Stream Type LIVE
Remaining Time 5:16
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Video content above is prompted by the following question:

    • What are some unmet needs in prostate cancer care today, particularly regarding diagnosis, risk stratification and treatment?
      • How can these gaps be addressed to improve patient outcomes?
    Related Videos
    Dr Louise Kostos answers a question during a Zoom video interview
    Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
    Dr Louise Kostos answers a question during a Zoom video interview
    An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
    Rana McKay, MD, on the role of radium-223 in the modern era
    Rana McKay, MD, on the role of radium-223 in the modern era
    Jason Hafron, MD, predicts coming advancements in bladder cancer
    Jason Hafron, MD, predicts coming advancements in bladder cancer
    Dr Louise Kostos answers a question during a Zoom video interview
    Dr Louise Kostos discusses PSA kinetics in mHSPC
    Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
    The importance of PSADT in high-risk, biochemically recurrent prostate cancer
    Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
    Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
    Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
    Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer
    Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
    Alicia Morgans, MD, MPH, on PSADT awareness and prostate cancer treatment initiation
    Dr Louise Kostos answers a question during a Zoom video interview
    Dr Louise Kostos discusses combination therapies in mHSPC
    Related Content
    FDA approves expanded label for 177Lu-PSMA-617 in mCRPC
    March 28th 2025

    FDA approves expanded label for 177Lu-PSMA-617 in mCRPC

    Hannah Clarke
    The approval is supported by positive data from the phase 3 PSMAfore trial.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    Data reinforce isodose MHFRT as standard of care radiotherapy regimen
    March 22nd 2025

    Data reinforce isodose MHFRT as standard of care radiotherapy regimen

    Hannah Clarke
    “These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.
    Dr. Schwen on focal therapies for prostate cancer
    January 11th 2024

    Dr. Schwen on focal therapies for prostate cancer

    Cleveland Clinic
    Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
    Trial launches of CBP/p300 inhibitor in mCRPC
    March 20th 2025

    Trial launches of CBP/p300 inhibitor in mCRPC

    Hannah Clarke
    Pocenbrodib is an oral, small molecule designed to inhibit the proteins CREBBP/EP300, which activate genes that promote cancer cell growth and proliferation.
    Exercise may improve erectile function in men with prostate cancer
    March 17th 2025

    Exercise may improve erectile function in men with prostate cancer

    Hannah Clarke
    “The study suggests that exercise would be an effective intervention for men with prostate cancer who express concern about sexual dysfunction, and that exercise medicine should be considered a key part of their treatment,” says Daniel Galvão, PhD.
    © 2025 MJH Life Sciences

    All rights reserved.